About us Contacts Drug interactions: 390 212
Drug search by name

Ivacaftor Granules and Jantoven

Determining the interaction of Ivacaftor Granules and Jantoven and the possibility of their joint administration.

Check result:
Ivacaftor Granules <> Jantoven
Relevance: 01.07.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.MONITOR: Coadministration with ivacaftor may theoretically increase the plasma concentrations of warfarin. The proposed mechanism is inhibition of CYP450 2C9-mediated metabolism of warfarin, which is primarily metabolized by the isoenzyme. The clinical significance of this potential interaction is unknown. MANAGEMENT: Caution is warranted and monitoring of INR is recommended when coadministration of warfarin and ivacaftor is required. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. References "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA. Cerner Multum, Inc. "Canadian Product Information." O 0 (2015): "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA. Cerner Multum, Inc. "Australian Product Information." O 0 Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 View all 5 references

Professional:

MONITOR: Coadministration with ivacaftor may theoretically increase the plasma concentrations of warfarin. The proposed mechanism is inhibition of CYP450 2C9-mediated metabolism of warfarin, which is primarily metabolized by the isoenzyme. The clinical significance of this potential interaction is unknown.

MANAGEMENT: Caution is warranted and monitoring of INR is recommended when coadministration of warfarin and ivacaftor is required. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.

References
  • "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
  • Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):
  • "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
  • Cerner Multum, Inc. "Australian Product Information." O 0
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Ivacaftor Granules

Generic Name: ivacaftor

Brand name: Kalydeco

Synonyms: Ivacaftor

Jantoven

Generic Name: warfarin

Brand name: Coumadin, Jantoven

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction